Gaush Meditech (HKSE:02407) Buildings And Improvements : HK$34.6 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Gaush Meditech Buildings And Improvements?

Gaush Meditech's quarterly buildings and improvements declined from Dec. 2022 (HK$29.2 Mil) to Jun. 2023 (HK$0.0 Mil) but then increased from Jun. 2023 (HK$0.0 Mil) to Dec. 2023 (HK$34.6 Mil).

Gaush Meditech's annual buildings and improvements increased from Dec. 2021 (HK$17.8 Mil) to Dec. 2022 (HK$29.2 Mil) and increased from Dec. 2022 (HK$29.2 Mil) to Dec. 2023 (HK$34.6 Mil).

Gaush Meditech Buildings And Improvements Historical Data

The historical data trend for Gaush Meditech's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gaush Meditech Buildings And Improvements Chart

Gaush Meditech Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Buildings And Improvements

3.49

7.39

17.82

29.18

34.64

Gaush Meditech Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Buildings And Improvements	Get a 7-Day Free Trial			17.82	27.01	29.18	-	34.64

Gaush Meditech Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Gaush Meditech (HKSE:02407) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gaush Meditech Ltd (HKSE:02407) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

F7Y:Germany

Address

No.11 Dongzhimen South Avenue, Room 1901, Building A, Zhonghui Plaza, Dongcheng District, Beijing, CHN

Website

https://www.gaush.com

Gaush Meditech Ltd is a provider of a broad spectrum of ophthalmic medical devices. The segments of the company include 1) Proprietary products segment develops and produces surgical equipment and related supporting software, intra-optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables independently; 2) Distribution products segment sells multi-function diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment and related supporting consumables produced by ophthalmic medical equipment manufacturers; 3) Technical services segment provides warranty services, maintenance services and after-sales services related consumables; and 4) Others segment.

Executives

Orbimed Advisors Iii Limited	2102 Investment manager
Orbimed Asia Gp Iii, L.p.	2102 Investment manager
Orbimed Asia Partners Iii, L.p.	2102 Investment manager
Gao Tieta	2201 Interest of corporation controlled by you
Gaush Holding Ltd	2101 Beneficial owner
Cuprite Gem Investments Ltd	2101 Beneficial owner
Warburg Pincus (bermuda) Private Equity Gp Ltd.	2201 Interest of corporation controlled by you
Warburg Pincus (cayman) China-southeast Asia Ii Gp Llc	2201 Interest of corporation controlled by you
Warburg Pincus (cayman) China-southeast Asia Ii Gp, L.p.	2201 Interest of corporation controlled by you
Warburg Pincus China-southeast Asia Ii (cayman), L.p.	2201 Interest of corporation controlled by you
Warburg Pincus Partners Ii (cayman), L.p.	2201 Interest of corporation controlled by you

Gaush Meditech (HKSE:02407) Headlines

No Headlines